Press

The latest news about enGene's progress

enGene Announces positive preliminary phase 1/2 data with eg-70 in bcg-unresponsive non-muscle invasive bladder cancer

enGene Inc., a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues enabled by it proprietary DDX platform, today announced positive results from its LEGEND study, a first-in-human Phase 1/2 clinical trial of EG-70 for the treatment of high-grade Non-Muscle Invasive Bladder Cancer (NMIBC) in patients with carcinoma in situ (CIS) that are BCG-unresponsive.

enGene ANNOUNCES POSTER PRESENTATION AT THE SOCIETY OF UROLOGIC ONCOLOGY 2021 ANNUAL MEETING

enGene Inc., a clinical-stage biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, today announced a poster presentation at the upcoming Society of Urologic Oncology Annual Meeting being held from December 1 to December 3, 2021.

enGene Announces FIRST-in-HUMAN dosing of eg-70 for the treatment of non-muscle invasive bladder cancer in phase 1/2 clinical trial

enGene Inc., a clinical-stage biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enable by its proprietary DDX platform, today announced the dosing of the first patient in the LEGEND study, a first in human Phase 1/2 clinical trial of EG-70 in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

Contact